Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Outlook Therapeutics (OTLK) stock
Learn how to easily invest in Outlook Therapeutics stock.
Outlook Therapeutics, Inc is a biotechnology business based in the US. Outlook Therapeutics shares (OTLK) are listed on the NASDAQ and all prices are listed in US Dollars. Outlook Therapeutics employs 8 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Outlook Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – OTLK – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Outlook Therapeutics stock price (NASDAQ: OTLK)Use our graph to track the performance of OTLK stocks over time.
Outlook Therapeutics shares at a glance
|Latest market close||$2.68|
|52-week range||$0.58 - $4.26|
|50-day moving average||$2.49|
|200-day moving average||$2.15|
|Wall St. target price||$5.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.89|
Buy Outlook Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Outlook Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Outlook Therapeutics price performance over time
|1 week (2021-07-15)||N/A|
|1 month (2021-06-25)||10.74%|
|3 months (2021-04-26)||18.06%|
|6 months (2021-01-22)||N/A|
|1 year (2020-07-22)||N/A|
|2 years (2019-07-22)||N/A|
|3 years (2018-07-22)||N/A|
|5 years (2016-07-22)||N/A|
Outlook Therapeutics financials
|Revenue TTM||$5.9 million|
|Gross profit TTM||$-26,341,998|
|Return on assets TTM||-104.25%|
|Return on equity TTM||-64034.97%|
|Market capitalisation||$430.5 million|
TTM: trailing 12 months
Shorting Outlook Therapeutics shares
There are currently 4.2 million Outlook Therapeutics shares held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 214.1% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Outlook Therapeutics shares can be evaluated.
Outlook Therapeutics's "short interest ratio" (SIR)
Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics shares currently shorted divided by the average quantity of Outlook Therapeutics shares traded daily (recently around 1.3 million). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.
However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics shares, or, against the total number of tradable Outlook Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Outlook Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Outlook Therapeutics shares, roughly 48 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Outlook Therapeutics.
Find out more about how you can short Outlook Therapeutics stock.
Outlook Therapeutics share dividends
We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months.
Have Outlook Therapeutics's shares ever split?
Outlook Therapeutics's shares were split on a 1:8 basis on 17 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Outlook Therapeutics shares which in turn could have impacted Outlook Therapeutics's share price.
Outlook Therapeutics share price volatility
Over the last 12 months, Outlook Therapeutics's shares have ranged in value from as little as $0.58 up to $4.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is 0.6817. This would suggest that Outlook Therapeutics's shares are less volatile than average (for this exchange).
Outlook Therapeutics overview
Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S. A. de C.
Stocks similar to Outlook Therapeutics
Outlook Therapeutics in the news
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
Outlook Therapeutics Names Trenary as President, CEO >OTLK
Frequently asked questionsWhat percentage of Outlook Therapeutics is owned by insiders or institutions?
Currently 48.37% of Outlook Therapeutics shares are held by insiders and 9.024% by institutions. How many people work for Outlook Therapeutics?
Latest data suggests 8 work at Outlook Therapeutics. When does the fiscal year end for Outlook Therapeutics?
Outlook Therapeutics's fiscal year ends in September. Where is Outlook Therapeutics based?
Outlook Therapeutics's address is: 4260 U.S. Route 1, Cranbury, NJ, United States, 08852 What is Outlook Therapeutics's ISIN number?
Outlook Therapeutics's international securities identification number is: US69012T2069 What is Outlook Therapeutics's CUSIP number?
Outlook Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68235M105
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert